StockData

Eli Lilly vs Pfizer

LLY and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LLY and PFE compare

Eli Lilly is the larger company, worth 8.2 times as much as Pfizer ($1.3T against $165B).

On earnings, Pfizer is cheaper: it trades at 38.0× trailing earnings, against 46.5× for Eli Lilly.

Eli Lilly grew revenue faster over the last twelve months (45.5% versus −0.21% for Pfizer).

Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with 6.8% at Pfizer.

Both pay dividends: Eli Lilly yields 0.36% and Pfizer 4.5%.

Eli Lilly scores higher on the StockData Score (19 against 9 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLLYPFE
Size and price
Market cap$1.3T$165B
Share price$1431.67$28.89
Change, 1 year40.0%11.7%
Change, 5 years450%−43.1%
Beta (5Y)0.26–
Employees50K75K
StockData Score
Total score19 (better)9
Valuation score2 (better)1
Growth score5 (better)1
Performance score5 (better)2
Health score4 (better)2
Dividend score33
Valuation
P/E46.5×38.0× (better)
P/S15.6×2.6× (better)
P/B33.4×1.9× (better)
EV/EBITDA37.7×16.3× (better)
P/FCF–15.0×
PEG0.94–
FCF yield–6.7%
Fair value$1134.58$18.86
Margin of safety−26.2% (better)−53.1%
Growth
Revenue growth (TTM)45.5% (better)−0.21%
Revenue growth, 5Y average21.6% (better)8.5%
Net income growth (TTM)49.8% (better)−59.7%
EPS growth (TTM)50.7% (better)−59.6%
EPS growth, 5Y average27.6% (better)−3.6%
Profitability
Gross margin83.6% (better)73.2%
Net margin31.9% (better)6.8%
FCF margin–17.2%
Return on equity86.1% (better)5.0%
Financial health
Debt / equity1.230.74 (better)
Net debt / EBITDA1.21 (better)4.07
Current ratio1.39 (better)1.27
Altman Z-score8.59 (better)2.00
Piotroski F-score7 (better)6
Dividends and buybacks
Dividend yield0.36%4.5% (better)
Payout ratio21.7%–
Years of dividend growth915 (better)
Dividend growth, 5Y average15.2% (better)2.4%
Buyback yield0.43%–
Shareholder yield0.80%4.5% (better)
Ownership
Held by institutions83.8%67.2%
Held by insiders10.4%0.03%
Insider net buying, 12 months−$373M$2.8M (better)
Superinvestors holding3 (better)2
Short interest, % of float0.86%2.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.